Skip to main content

Invasive Fungal Infection

3
Pipeline Programs
5
Companies
4
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

MSD
MSDIreland - Ballydine
2 programs
1
Posaconazole IV 6 mg/kgPhase 21 trial
Evaluate Three Methods for Diagnosis of Invasive Fungal Infection in Chinese Patients After HSCTN/A1 trial
Active Trials
NCT00460330Unknown120Est. Dec 2008
NCT04665037Recruiting40Est. Dec 2026
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
2 programs
1
Posaconazole IV 6 mg/kgPhase 2
Evaluate Three Methods for Diagnosis of Invasive Fungal Infection in Chinese Patients After HSCTN/A
Biosergen
BiosergenSweden - Solna
1 program
1
BSG005Phase 1/21 trial
Active Trials
NCT06678113Recruiting15Est. Apr 2026
Merck & Co.
Merck & Co.RAHWAY, NJ
1 program
Evaluate Three Methods for Diagnosis of Invasive Fungal Infection in Chinese Patients After HSCTN/A
Astellas
AstellasChina - Shenyang
1 program
Isavuconazonium sulfateN/A1 trial
Active Trials
NCT03066011Completed2,015Est. Apr 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
MSDPosaconazole IV 6 mg/kg
BiosergenBSG005
AstellasIsavuconazonium sulfate
MSDEvaluate Three Methods for Diagnosis of Invasive Fungal Infection in Chinese Patients After HSCT

Clinical Trials (4)

Total enrollment: 2,190 patients across 4 trials

NCT04665037MSDPosaconazole IV 6 mg/kg

Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127)

Start: Feb 2022Est. completion: Dec 202640 patients
Phase 2Recruiting
NCT06678113BiosergenBSG005

Study to Assess the Safety and Efficacy of Intravenous BSG005 in Patients With Invasive Fungal Infection

Start: Jul 2024Est. completion: Apr 202615 patients
Phase 1/2Recruiting
NCT03066011AstellasIsavuconazonium sulfate

Registry of Patients Treated With Systemic Mold-Active Triazoles

Start: Mar 2017Est. completion: Apr 20202,015 patients
N/ACompleted
NCT00460330MSDEvaluate Three Methods for Diagnosis of Invasive Fungal Infection in Chinese Patients After HSCT

Evaluate Three Methods for Diagnosis of Invasive Fungal Infection in Chinese Patients After HSCT

Start: Apr 2007Est. completion: Dec 2008120 patients
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 2,190 patients
5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.